Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.32 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.32 |
| ▸ | SLC18A3 | Q16572 | 2/20 | 0.31 |
| ▸ | PLD2 | O14939 | 1/20 | 0.30 |
| ▸ | PLD1 | Q13393 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13640979 | 0.80 | HRH3 (0.47) | SIGMAR1OPRM1SLC18A3PLD1 | |
| SCHEMBL13643924 | 0.78 | DRD2 (0.32) | SIGMAR1OPRM1 | |
| SCHEMBL13226740 | 0.77 | SIGMAR1 (0.34) | SIGMAR1OPRM1 | |
| SCHEMBL13640762 | 0.77 | OPRM1 (0.53) | OPRM1PLD2PLD1 | |
| SCHEMBL13640989 | 0.74 | SIGMAR1 (0.51) | SIGMAR1OPRM1SLC18A3 | |
| SCHEMBL13640814 | 0.74 | SIGMAR1 (0.51) | SIGMAR1OPRM1SLC18A3 | |
| SCHEMBL13640906 | 0.69 | MCHR2 (0.51) | SIGMAR1SLC18A3PLD1 | |
| SCHEMBL13640885 | 0.69 | MCHR2 (0.51) | SIGMAR1SLC18A3PLD1 | |
| SCHEMBL13640884 | 0.69 | MCHR2 (0.51) | SIGMAR1SLC18A3PLD1 | |
| SCHEMBL13641129 | 0.69 | KDM4E (0.40) | SIGMAR1OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8497295-B2 | Spiroindoline modulators of muscarinic receptors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-07-30 | — | — | US | disclosed |
| US-20120283243-A1 | Spiroindoline Modulators of Muscarinic Receptors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120283243-A1 | Spiroindoline Modulators of Muscarinic Receptors | CHRM3, CHRM2, CHRM5 | SIGMAR1 253/4885OPRM1 177/4885SLC18A3 319/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.